Decreased tryptophan metabolism in patients with autism spectrum disorders

BackgroundAutism spectrum disorders (ASDs) are relatively common neurodevelopmental conditions whose biological basis has been incompletely determined. Several biochemical markers have been associated with ASDs, but there is still no laboratory test for these conditions.MethodsWe analyzed the metabolic profile of lymphoblastoid cell lines from 137 patients with neurodevelopmental disorders with or without ASDs and 78 normal individuals, using Biolog Phenotype MicroArrays.ResultsMetabolic profiling of lymphoblastoid cells revealed that the 87 patients with ASD as a clinical feature, as compared to the 78 controls, exhibited on average reduced generation of NADH when tryptophan was the sole energy source. The results correlated with the behavioral traits associated with either syndromal or non-syndromal autism, independent of the genetic background of the individual. The low level of NADH generation in the presence of tryptophan was not observed in cell lines from non-ASD patients with intellectual disability, schizophrenia or conditions exhibiting several similarities with syndromal autism except for the behavioral traits. Analysis of a previous small gene expression study found abnormal levels for some genes involved in tryptophan metabolic pathways in 10 patients.ConclusionsTryptophan is a precursor of important compounds, such as serotonin, quinolinic acid, and kynurenic acid, which are involved in neurodevelopment and synaptogenesis. In addition, quinolinic acid is the structural precursor of NAD+, a critical energy carrier in mitochondria. Also, the serotonin branch of the tryptophan metabolic pathway generates NADH. Lastly, the levels of quinolinic and kynurenic acid are strongly influenced by the activity of the immune system. Therefore, decreased tryptophan metabolism may alter brain development, neuroimmune activity and mitochondrial function. Our finding of decreased tryptophan metabolism appears to provide a unifying biochemical basis for ASDs and perhaps an initial step in the development of a diagnostic assay for ASDs.

[1]  Rosa Seijo,et al.  Age at diagnosis of autism spectrum disorders. , 2012, The Journal of pediatrics.

[2]  A. Shojaie,et al.  Metabolomic Profiling Reveals a Role for Androgen in Activating Amino Acid Metabolism and Methylation in Prostate Cancer Cells , 2011, PloS one.

[3]  David Quig,et al.  Nutritional and metabolic status of children with autism vs. neurotypical children, and the association with autism severity , 2011, Nutrition & metabolism.

[4]  Trevor Sharp,et al.  A review of central 5-HT receptors and their function , 1999, Neuropharmacology.

[5]  G. B. Schaefer,et al.  Clinical genetics evaluation in identifying the etiology of autism spectrum disorders , 2008, Genetics in Medicine.

[6]  J. Schaechter,et al.  Serotonin release varies with brain tryptophan levels , 1990, Brain Research.

[7]  Elizabeth A. Daubert,et al.  Serotonin: a regulator of neuronal morphology and circuitry , 2010, Trends in Neurosciences.

[8]  K. Sugden,et al.  Genes within the serotonergic system are differentially expressed in human brain , 2009, BMC Neuroscience.

[9]  J. Miles.  Autism spectrum disorders—A genetics review , 2011, Genetics in Medicine.

[10]  C. Rice.  Prevalence of autism spectrum disorders - Autism and Developmental Disabilities Monitoring Network, United States, 2006. , 2009, Morbidity and mortality weekly report. Surveillance summaries.

[11]  C. McDougle,et al.  High nitric oxide production in autistic disorder: a possible role for interferon-γ , 2004, Biological Psychiatry.

[12]  T. Stone,et al.  Endogenous kynurenines as targets for drug discovery and development , 2002, Nature Reviews Drug Discovery.

[13]  อนิรุธ สืบสิงห์,et al.  Data Mining Practical Machine Learning Tools and Techniques , 2014 .

[14]  G. Anderson,et al.  Genetics of childhood disorders: XLV. Autism, part 4: serotonin in autism. , 2002, Journal of the American Academy of Child and Adolescent Psychiatry.

[15]  Chin-Fu Chen,et al.  Regulation of Cellular Metabolism and Cytokines by the Medicinal Herb Feverfew in the Human Monocytic THP-1 Cells , 2007, Evidence-based complementary and alternative medicine : eCAM.

[16]  D. Rossignol,et al.  Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis , 2011, Molecular Psychiatry.

[17]  M. Cuccaro,et al.  Autism and maternally derived aberrations of chromosome 15q. , 1998, American journal of medical genetics.

[18]  N. Minshew,et al.  The new neurobiology of autism: cortex, connectivity, and neuronal organization. , 2007, Archives of neurology.

[19]  C. Rice,et al.  Autism and Developmental Disabilities Monitoring Network Surveillance Year 2000 Principal Investigators , 2012 .

[20]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[21]  G. Churchill.  Fundamentals of experimental design for cDNA microarrays , 2002, Nature Genetics.

[22]  John C. Lindon,et al.  Urinary metabolic phenotyping differentiates children with autism from their unaffected siblings and age-matched controls. , 2010, Journal of proteome research.

[23]  D. Zuroff,et al.  The Effect of Tryptophan on Social Interaction in Everyday Life: A Placebo-Controlled Study , 2001, Neuropsychopharmacology.

[24]  E. Fernell,et al.  Altered tryptophan and alanine transport in fibroblasts from boys with attention-deficit/hyperactivity disorder (ADHD): an in vitro study , 2011, Behavioral and Brain Functions.

[25]  E. Deneris,et al.  A transient placental source of serotonin for the fetal forebrain , 2011, Nature.

[26]  M. Ganz,et al.  The lifetime distribution of the incremental societal costs of autism. , 2007, Archives of pediatrics & adolescent medicine.

[27]  Yudong D. He,et al.  Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer , 2001, Nature Biotechnology.

[28]  H. Savaş,et al.  Changes in nitric oxide levels and antioxidant enzyme activities may have a role in the pathophysiological mechanisms involved in autism. , 2003, Clinica chimica acta; international journal of clinical chemistry.

[29]  R. Rothermel,et al.  Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children , 1999, Annals of neurology.

[30]  H. Engeland,et al.  Minicolumnar abnormalities in autism , 2006, Acta Neuropathologica.

[31]  Andreas Büttner,et al.  Analysis of tryptophan hydroxylase I and II mRNA expression in the human brain: a post-mortem study. , 2007, Journal of psychiatric research.

[32]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Mark F. Bear,et al.  The Autistic Neuron: Troubled Translation? , 2008, Cell.

[34]  J. Stockman.  Association between Microdeletion and Microduplication at 16p11.2 and Autism , 2009 .

[35]  Thomas Bourgeron,et al.  A synaptic trek to autism , 2009, Current Opinion in Neurobiology.

[36]  M. Casanova.  The Neuropathology of Autism , 2007, Brain pathology.

[37]  Matthew P. Anderson,et al.  Bridging from Cells to Cognition in Autism Pathophysiology: Biological Pathways to Defective Brain Function and Plasticity , 2008 .

[38]  S. Horvath,et al.  Transcriptomic Analysis of Autistic Brain Reveals Convergent Molecular Pathology , 2011, Nature.

[39]  M. Mattson,et al.  Energetics and oxidative stress in synaptic plasticity and neurodegenerative disorders , 2002, NeuroMolecular Medicine.

[40]  J. Stockman,et al.  Neuron Number and Size in Prefrontal Cortex of Children With Autism , 2013 .

[41]  P. Clemons,et al.  Assay of the Multiple Energy-Producing Pathways of Mammalian Cells , 2011, PloS one.